Hormone replacement therapy and cervical cancer: a systematic review of the literature

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424
   PubMed Web of Science ®Google Scholar
• Arbyn M, Castellsagué X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675–86
   PubMed Web of Science ®Google Scholar
• Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health 2020;8:e191–203
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Surveillance, Epidemiology and End Results Program Cancer stat facts: cervical cancer. (2018) //seer.cancer.gov/statfacts/html/cervix.html (Accessed November 11, 2018)
   Google Scholar
• NCCN Guidelines Version 1.2020 Cervical Cancer, 2020
   Google Scholar
• Tabata M, Ichinoe K, Sakuragi N, et al. Incidence of ovarian metastasis in patients with cancer of uterine cervix. Gynecol Oncol 1987;28:255–61
   PubMed Web of Science ®Google Scholar
• Shimada M, Kigawa J, Nishimura R, et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol 2006;101:234–7
   PubMed Web of Science ®Google Scholar
• Natsume N, Aoki Y, Kase H, et al. Ovarian metastasis in stage IB and II cervical adenocarcinoma. Gynecol Oncol 1999;74:255–8
   PubMed Web of Science ®Google Scholar
• Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod 2003;18:117–21
   PubMed Web of Science ®Google Scholar
• Ibeanu O, Modesitt SC, Ducie J, et al. Hormone replacement therapy in gynecologic cancer survivors: why not?. Gynecol Oncol 2011;122:447–e454
   PubMed Web of Science ®Google Scholar
• Hinds L, Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int 2010;16:89–93
   PubMedGoogle Scholar
• Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol 2003;157:923–9
   PubMed Web of Science ®Google Scholar
• Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159:1061–6
   PubMed Web of Science ®Google Scholar
• Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol 1999;52:303–7
   PubMed Web of Science ®Google Scholar
• Villa P, Amar ID, Bottoni C, et al. The impact of combined nutraceutical supplementation on quality of life and metabolic changes during the menopausal transition: a pilot randomized trial. Arch Gynecol Obstet 2017;296:791–801
   PubMed Web of Science ®Google Scholar
• Vavilis D, Athanatos D, Theodoridis TD, et al. Attitudes of Greek gynecologists to prescription of hormone replacement therapy for survivors of cervical cancer. Int J Gynaecol Obstet 2009;107:66–7
   PubMed Web of Science ®Google Scholar
• Everhov ÅH, Nyberg T, Bergmark K, et al. Hormone therapy after uterine cervical cancer treatment: a Swedish population-based study. Menopause 2015;22:633–9
   PubMed Web of Science ®Google Scholar
• Rauh LA, Pannone AF, Cantrell LA. Hormone replacement therapy after treatment for cervical cancer: are we adhering to standard of care? Gynecol Oncol 2017;147:597–600
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P): elaboration and explanation. BMJ 2015;349:g7647
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6
   PubMed Web of Science ®Google Scholar
• Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620–35
   PubMedGoogle Scholar
• Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989;44:833–9
   PubMed Web of Science ®Google Scholar
• Parazzini F, La Vecchia C, Negri E, et al. Case-control study of oestrogen replacement therapy and risk of cervical cancer. BMJ 1997;315:85–8
   PubMed Web of Science ®Google Scholar
• Persson I, Yuen J, Bergkvist L, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy–long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327–32
   PubMed Web of Science ®Google Scholar
• Lacey JV, Jr, Brinton LA, Barnes WA, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000;77:149–54
   PubMed Web of Science ®Google Scholar
• Anderson GL, Judd HL, Kaunitz AM, et al. Women’s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 2003;290:1739–48
   PubMed Web of Science ®Google Scholar
• Schneider C, Jick SS, Meier CR. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009;12:514–24
   PubMed Web of Science ®Google Scholar
• Jaakkola S, Pukkala E, K Lyytinen H, et al. Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer. Int J Cancer 2012;131:E537–43
   PubMed Web of Science ®Google Scholar
• Roura E, Travier N, Waterboer T, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC Cohort. PLoS One 2016;11:e0147029 eCollection 2016 Erratum in: PLoS One. 2016;11(3):e0151427. PMID: 26808155
   PubMed Web of Science ®Google Scholar
• Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987;26:169–77
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Chlebowski RR, Anderson GG. Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 2012;104:517–27
   PubMed Web of Science ®Google Scholar
• Hersh AA, Stefanick MM, Stafford RR. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47–53
   PubMed Web of Science ®Google Scholar
• Steinkellner SE, Denison SL, Eldridge LL, et al. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women’s Health Initiative. Menopause 2012;19:616–21
   PubMed Web of Science ®Google Scholar
• Depypere H, Pintiaux A, Desreux J, et al. Coping with menopausal symptoms: an internet survey of Belgian postmenopausal women. Maturitas 2016;90:24–30
   PubMed Web of Science ®Google Scholar
• Bodner K, Laubichler P, Kimberger O, et al. Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res 2010;30:1341–5
   PubMed Web of Science ®Google Scholar
• Martin JD, Hähnel R, McCartney AJ, et al. The influence of estrogen and progesterone receptors on survival in patients with carcinoma of the uterine cervix. Gynecol Oncol 1986;23:329–35
   PubMed Web of Science ®Google Scholar
• Riley RR, Duensing S, Brake T, et al. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 2003;63:4862–71
   PubMed Web of Science ®Google Scholar
• Shai A, Brake T, Somoza C, et al. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 2007;67:1626–35
   PubMed Web of Science ®Google Scholar
• Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci USA 1996;93:2930–5
   PubMed Web of Science ®Google Scholar
• Pater A, Bayatpour M, Pater MA. Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. Am J Obstet Gynecol 1990;162:1099–103
   PubMed Web of Science ®Google Scholar
• Chan W-K, Klock G, Bernard H-U. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 1989;63:3261–9
   PubMed Web of Science ®Google Scholar
• Matlashewski G, Schneider J, Banks L, et al. Human papillomavirus type 16 DNA cooperates with activated ras oncogene in transforming primary cells. Embo J 1987;6:1741–6
   PubMed Web of Science ®Google Scholar
• Crook T, Storey A, Almond N, et al. Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. Proc Natl Acad Sci USA 1988;85:8820–4
   PubMed Web of Science ®Google Scholar
• Ferenczy A, Gelfand MM, Franco E, et al. Human papillomavirus infection in postmenopausal women with and without hormone therapy. Obstet Gynecol 1997;90:7–11
   PubMed Web of Science ®Google Scholar
• Smith EM, Johnson SR, Figuerres EJ, et al. Is use of hormone replacement therapy associated with increased detection of human papillomavirus and potential risk of HPV-related genital cancers? Eur J Cancer Prev 1997;65:441–305
   Google Scholar
• Smith EM, Ritchie JM, Levy BT, et al. Prevalence and persistence of human papillomavirus in postmenopausal age women. Cancer Detect Prev 2003;27:472–80
   PubMedGoogle Scholar
• Vujovic S, Brincat M, Erel T, et al. EMAS position statement: managing women with premature ovarian failure. Maturitas 2010;67:91–3
   PubMed Web of Science ®Google Scholar
• Armeni E, Lambrinoudaki I, Ceausu I, et al. Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS). Maturitas 2016;89:63–72
   PubMed Web of Science ®Google Scholar
• Yasuda M, Kurabayashi T, Yamamoto Y, et al. Effect of hormone replacement therapy on bone and lipid metabolism in women oophorectomized for the treatment of gynecologic malignancies. Int J Gynaecol Obstet 1994;47:151–6
   PubMed Web of Science ®Google Scholar
• Kurabayashi T, Yahata T, Honda A, et al. Effect of long-term hormone replacement therapy on the bone in ovariectomized women with cancer. Int J Gynaecol Obstet 1998;60:271–7
   PubMed Web of Science ®Google Scholar
• Sun LM, Liang JA, Chang SN, et al. Estrogen decrease coronary artery disease risk in patients with cervical cancer after treatment. Gynecol Oncol 2012;127:186–90
   PubMed Web of Science ®Google Scholar
• Li C, Samsioe G, Iosif C. Quality of life in long-term survivors of cervical cancer. Maturitas 1999;32:95–102
   PubMed Web of Science ®Google Scholar
• Habeshaw T, Pinion SB. The incidence of persistent functioning endometrial tissue following successful radiotherapy for cervical carcinoma. Int J Gynecol Cancer 1992;2:332–5
   PubMed Web of Science ®Google Scholar
• Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010;65:190–1997
   PubMed Web of Science ®Google Scholar
• Sheehan JF, Schmitz HE, Towne J. Changes in the uterus after eradication of endometrial adenocarcinoma by radiotherapy. Arch Pathol 1943;39:237–45
   Google Scholar
• Grontoft O, Risberg B, Stenson S, Westholm B. Residual carcinoma after intracavitary irradiation of endometrial carcinoma, Stage I. A study of whole-organ sections. Acta Obstet Gynecol Scand 1982; 61:163–72
   PubMed Web of Science ®Google Scholar
• Ferenczy A. Studies on the cytodynamics of human endometrial regeneration. I. Scanning electron microscopy. Am J Obstet Gynecol 1976;124:64–74
   PubMed Web of Science ®Google Scholar
• Wachtel MM, Yang S, Dissanaike S, et al. Hormone replacement therapy, likely neither angel nor demon. PLoS One 2015;10:e0138556
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543–51
   PubMed Web of Science ®Google Scholar
• Sjögren LL, Mørch LL, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas 2016;91:25–35
   PubMed Web of Science ®Google Scholar
• Jensen PT, Froeding LP. Pelvic radiotherapy and sexual function in women. Transl Androl Urol 2015;4:186–e205
   PubMed Web of Science ®Google Scholar
• Hofsjö A, Bergmark K, Blomgren B, et al. Radiotherapy for cervical cancer – impact on the vaginal epithelium and sexual function. Acta Oncol 2018;57:338–45
   PubMed Web of Science ®Google Scholar
• Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;4:CD001500
   PubMedGoogle Scholar
• Candy B, Jones L, Vickerstaff V, et al. Interventions for sexual dysfunction following treatments for cancer in women. Cochrane Database Syst Rev 2016;2:CD005540
   PubMedGoogle Scholar
• Hancke K, Foeldi M, Zahradnik HP, et al. Estrogen replacement therapy after endometrial cancer: a survey of physician’s prescribing practice. Climacteric 2010;13:271–7
   PubMed Web of Science ®Google Scholar
• Vavillis D, Chatzigeorgiou K, Goulis D, et al. Hormonal replacement therapy in ovarian cancer survivors: A survey among Greek gynaecologists. Eur J Gynaecol Oncol 2011;32:538–41
   PubMed Web of Science ®Google Scholar
• Vavillis D, Tsolakidis D, Goulis DG, et al. Hormone therapy for postmenopausal endometrial cancer survivors: a survey among Greek obstetricians-gynaecologists. Eur J Gynaecol Oncol 2011;32:81–3
   PubMed Web of Science ®Google Scholar